Alimera Sciences completes patient enrollment for phase 4 Yutiq Synchronicity study

Alimera Sciences has completed enrollment for its Synchronicity study, a prospective, open-label trial to evaluate the safety and efficacy of Yutiq for chronic noninfectious uveitis and related inflammation.
“We are pleased to reach the enrollment target for this phase 4 open-label study only a few short months after our acquisition of Yutiq,” Rick Eiswirth, Alimera’s president and CEO, said in a company press release.
Yutiq is a sustained-release 0.18 mg fluocinolone acetonide intravitreal implant that uses continuous microdosing technology, designed to release sub-microgram

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.